Lumos Pharma
99 articles about Lumos Pharma
-
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
8/9/2022
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the quarter ended June 30, 2022.
-
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022
7/27/2022
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its second quarter 2022 financial results after market close on Tuesday, August 9, 2022.
-
Lumos Pharma to Participate in Upcoming Investor Conferences - May 16, 2022
5/16/2022
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investors conferences:
-
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
5/10/2022
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the quarter ended March 31, 2022 and clinical development updates.
-
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
5/5/2022
Lumos Pharma, Inc today announced a collaboration with Laura Dichtel, MD of Massachusetts General Hospital to evaluate the orally administered growth hormone (GH) secretagogue, LUM-201, in Nonalcoholic Fatty Liver Disease (NAFLD).
-
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
4/26/2022
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its first quarter 2022 financial results after market close on Tuesday, May 10, 2022.
-
Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
4/11/2022
Lumos Pharma, Inc. announced this morning achievement of the 50% randomization milestone for our Phase 2 OraGrowtH210 Trial evaluating orally administered LUM-201.
-
Lumos Pharma to Participate in the Cantor Rare Disease Symposium
3/23/2022
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that John McKew, PhD, President and Chief Scientific Officer of Lumos Pharma, will participate in a panel discussion at the Cantor Rare Disease Symposium at the end of March 2022.
-
Lumos Pharma to Participate in Upcoming Investor Conferences in March 2022
3/10/2022
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the 34th Annual Roth Conference and the Maxim 2022 Virtual Growth Conference in March.
-
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
3/10/2022
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the year ended December 31, 2021, announced plans to conduct interim analyses of its OraGrowtH210 and OraGrowtH212 Trials, and provided an update on clinical activities and financial guidance for 2022.
-
Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022
2/23/2022
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its full year 2021 financial results after market close on Thursday, March 10, 2022.
-
Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
1/5/2022
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13, 2022.
-
Lumos Pharma to Participate in Upcoming Investor Conferences - Nov 10, 2021
11/10/2021
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investor conferences.
-
In November 2019, Emory realized this experimental drug could have significant potential in respiratory viruses such as COVID-19.
-
Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates
11/3/2021
Lumos Pharma, Inc. today announced financial results for the third quarter ending September 30, 2021 and provided an update on clinical progress
-
Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
10/21/2021
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its third quarter 2021 financial results after market close on Wednesday, November 3, 2021.
-
Lumos Pharma to Participate in September 2021 Investor Conferences
9/2/2021
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference and the Cantor Virtual Global Healthcare Conference in September.
-
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
8/5/2021
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the second quarter ending June 30, 2021 and provided an update on clinical and corporate activities.
-
Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
8/2/2021
Lumos Pharma, Inc. has announced that current Chief Operating Officer and Chief Scientific Officer, John McKew, PhD, was promoted to President of Lumos Pharma effective August 1, 2021 as part of the Company’s planned succession.
-
Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board
7/26/2021
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach, M.D., Ph.D., accepted his appointment to the Company’s Clinical Scientific Advisory Board (CSAB) effective July 15, 2021.